News Genmab A/S

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 19/01/2026 GMT			5-day change	1st Jan Change
2,043.00 ^DKK	-6.50%		-5.50%	+0.79%

01-19	SHB: Overreaction in the Market to Genmab's Epkinly Study	FW
01-19	Genmab's Phase 3 Study with Epcoritamab Fails to Meet Overall Survival Endpoint	FW

01-19	AbbVie Announces Topline Results for Epcoritamab (DuoBody(R) CD3xCD20) from Phase 3 EPCORE(R) DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)	AQ
01-19	Genmab Announces Topline Results for Epcoritamab from Phase 3 EPCORE DLBCL-1 Trial in Patients with Relapsed, Refractory Diffuse Large B-cell Lymphoma	AQ
01-19	SHB: Overreaction in the Market to Genmab's Epkinly Study	FW
01-19	Genmab's Phase 3 Study with Epcoritamab Fails to Meet Overall Survival Endpoint	FW
01-19	Genmab's Epcoritamab Improves Progression-free Survival in Lymphoma Patients, Phase 3 Data Shows	MT
01-16	Genmab A/S Announces Topline Results for Epcoritamab (DuoBody CD3xCD20) from Phase 3 EPCORE DLBCL-1 Trial in Patients with Relapsed Refractory Diffuse Large B-Cell Lymphoma	CI
01-16	AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma	CI
01-16	AbbVie, Genmab Lymphoma Treatment Shows Improved Progression-Free Survival	DJ
01-16	Genmab Says Epcoritamab Improves Progression-Free Survival in Phase 3 Lymphoma Study	MT
01-16	Genmab and AbbVie's blood cancer drug fails to improve survival in late-stage study	RE
01-16	Genmab says phase 3 trial for epcoritamab did not reach statistical significance	RE
01-16	Genmab's blood cancer drug fails main goal in late-stage study	RE
01-16	Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)	BU
01-16	Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)	GL
01-16	Genmab Stock Trading Halted, Pending Material News Release	MT
01-15	Jyske Bank Raises Genmab Target Price to 2,300 Danish Kroner (2,000), Reiterates Hold - BN	FW
01-14	Genmab A/S Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 03:45 PM
01-13	Genmab A/S : JP Morgan 2026 Presentation	PU
01-08	UBS Raises Price Target for Genmab to 2,750 Danish Kroner (from 2,700), Reiterates Buy	FW
01-07	Genmab A/S Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence	CI
01-07	Genmab partners with Anthropic to accelerate research and development through agentic AI	RE
01-07	Genmab to Advance R&D Processes via AI Under New Anthropic Partnership	MT
01-07	Genmab, Anthropic to Use AI Tools in Clinical Development	MT
01-07	Genmab partners with Anthropic to accelerate R&D via agentic AI	RE
01-07	Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

Genmab advances on earnings strength and pipeline while lower valuation opens upside

November 07, 2025 at 03:01 pm

Genmab: From now on, courage to the most patient

April 01, 2025 at 03:57 pm